Patents by Inventor Yusuke Asoh
Yusuke Asoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9133140Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.Type: GrantFiled: August 20, 2009Date of Patent: September 15, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Shinji Marumoto, Toyoki Nishimata, Masayuki Ebisawa, Yusuke Asoh, Yasuo Fukushima, Mikio Kato
-
Patent number: 8754118Abstract: [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein R1 is a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and R2 is a hydrogen atom or a C1-C3 alkoxy group).Type: GrantFiled: July 30, 2013Date of Patent: June 17, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Juri Yoshida, Yusuke Asoh
-
Patent number: 8642640Abstract: The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1-C3 alkyl group; R2 represents a hydroxy-C1-C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1-C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like, —R5 represents a sulfamoyl group or a C1-C3 alkylsulfonyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.Type: GrantFiled: October 7, 2009Date of Patent: February 4, 2014Assignees: Exelixis, Inc., Daiichi Sankyo Company, LimitedInventors: John Nuss, Matthew Williams, Raju Mohan, Richard Martin, Tie-Lin Wang, Hiroyuki Tsuruoka, Kazumasa Aoki, Masatoshi Honzumi, Yusuke Asoh, Keiji Saito, Tsuyoshi Homma
-
Publication number: 20140024696Abstract: [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein R1 is a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and R2 is a hydrogen atom or a C1-C3 alkoxy group).Type: ApplicationFiled: July 30, 2013Publication date: January 23, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Juri Yoshida, Yusuke Asoh
-
Patent number: 8524918Abstract: [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein R1 is a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and R2 is a hydrogen atom or a C1-C3 alkoxy group).Type: GrantFiled: October 8, 2009Date of Patent: September 3, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Juri Yoshida, Yusuke Asoh
-
Publication number: 20120295943Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: August 20, 2009Publication date: November 22, 2012Inventors: Shinji Marumoto, Toyoki Nishimata, Masayuki Ebisawa, Yusuke Asoh, Yasuo Fukushima, Mikio Kato
-
Publication number: 20120122941Abstract: Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: August 20, 2009Publication date: May 17, 2012Inventors: Shinji Marumoto, Toyoki Nishimata, Masayuki Ebisawa, Yusuke Asoh, Yasuo Fukushima, Mikio Kato
-
Publication number: 20110263544Abstract: The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1-C3 alkyl group; R2 represents a hydroxy-C1-C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1-C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like, —R5 represents a sulfamoyl group or a C1-C3 alkylsulfonyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.Type: ApplicationFiled: October 7, 2009Publication date: October 27, 2011Applicants: DAIICHI SANKYO COMPANY, LIMITED, EXELIXIS, INC.Inventors: John Nuss, Matthew Williams, Raju Mohan, Richard Martin, Tie-Lin Wang, Hiroyuki Tsuruoka, Kazumasa Aoki, Masatoshi Honzumi, Yusuke Asoh, Keiji Saito, Tsuyoshi Homma
-
Publication number: 20100093826Abstract: [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. [Means for Resolution] An atropisomer of a compound represented by the following general formula (I): (wherein R1 is a C1-C3 alkyl group or a hydroxy-C1-C3 alkyl group; and R2 is a hydrogen atom or a C1-C3 alkoxy group).Type: ApplicationFiled: October 8, 2009Publication date: April 15, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazumasa Aoki, Hiroyuki Tsuruoka, Noriyuki Hayashi, Juri Yoshida, Yusuke Asoh